Introduction
The Dermatology Market Outlook to 2011 provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes. The in-depth 6-year epidemiology and product sales forecasts in this report will enable you to plan effectively, evaluate changes in the competitive positions of leading companies and accurately benchmark your position.

Key findings of this new report
• The psoriasis market is forecast to post the most aggressive growth rates over the period to 2011, as Raptiva and Daivobet drive growth over the forecast period. Psoriasis treatments are forecast to expand sales at a CAGR of 12.5%, reaching sales of $1.9bn in 2011.
• With Roaccutane and Diane facing generic competition, the branded oral acne treatments market is set to decline over the forecast period. Forecast sales of the acne market are estimated at $2.7bn in 2011.
• The corticosteroid market was valued at $2,783m in 2005, 5.8% up on year previous sales of $2,630m. Triple combination anti-infective/corticosteroid therapies are driving growth, whilst widespread genericization is restraining growth of the class as a whole.

The 5 Major dermatological indications covered are:
• Acne
• Psoriasis
• Infectious diseases of the skin
• Dermatitis
• Rosacea

Your questions answered
• What will be the major growth indications in the dermatology area over the period 2006-11?
• How have recent major launches from companies such as Novartis, Astellas and Genentech performed?
• Which companies will become the key players in the dermatology area over the period 2006-11?
• Which products will be impacted by generic competitors over the period 2006-11?
• What will the competitive landscape in acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infections look like in 2011?

This report will enable you to...
• Quantify patient potential, assess treatment trends and sales patterns with this report's in-depth coverage of the 5 major dermatological indications, the US, Japanese and top EU 5 markets and the top 10 leading companies.
• Forecast sales of the major products in the dermatology area over the period 2006-11 in major dermatological indications, classes of treatments and by company.
• Evaluate how market share of leading companies, such as Novartis, GlaxoSmithKline and Schering Plough, will change over the next 6 years, and assess your competitive position within the market.
• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of dermatological treatments including corticosteroids, anti-infectives, acne treatments and psoriasis treatments.